Stocks News

LAST PRICE
273.0100
TODAY'S CHANGE (%)
Trending Down-0.5300 (-0.1938%)

Bid / Lots
273.0100/ 11
Ask / Lots
274.9900/ 1
Open / Previous Close
270.6300 / 273.5400
Day Range
Low 269.6450
High 274.8580
52 Week Range
Low 211.7100
High 329.7200
Volume
2,467,127
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 18, 2024
- DJ Amgen Is Maintained at Neutral by UBS, from 7:41AM ET on Thursday Apr 18, 2024 by Dow Jones
  7:41AM ET on Thursday Apr 18, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AMGN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 18, 2024 07:41 ET (11:41 GMT)
Apr 17, 2024
- --UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating, from 9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires
  9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires
  Companies Mentioned: AMGN
  09:57 AM EDT, 04/17/2024 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contac...
- DJ Amgen Is Maintained at Buy by TD Cowen, from 6:12AM ET on Wednesday Apr 17, 2024 by Dow Jones
  6:12AM ET on Wednesday Apr 17, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AMGN/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 17, 2024 06:12 ET (10:12 GMT)
Apr 16, 2024
- Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease, from 5:56PM ET on Tuesday Apr 16, 2024 by MT Newswires
  5:56PM ET on Tuesday Apr 16, 2024 by MT Newswires
  Companies Mentioned: AMGN
  05:56 PM EDT, 04/16/2024 (MT Newswires) -- Amgen (AMGN) said late Tuesday it is planning for the phase 3 trial of tezepelumab in chronic obstructive pulmonary disease, encouraged by the results of phase 2a proof-of-concept study. The company said th...
- AMGEN TO PRESENT TEZSPIRE(R) PHASE 2A COPD DATA AT ATS 2024, from 5:26PM ET on Tuesday Apr 16, 2024 by Dow Jones
  5:26PM ET on Tuesday Apr 16, 2024 by Dow Jones
  Companies Mentioned: AMGN
  
  AMGEN TO PRESENT TEZSPIRE(R) PHASE 2A COPD DATA AT ATS 2024
  
  PR Newswire
  
  THOUSAND OAKS, Calif., April 16, 2024
  
  Planning Underway for Phase 3 Development of Tezepelumab in COPD

Today
- --HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: GILD
- CureVac Begins Early Stage Portion of Investigational Vaccine Trial, from 11 hours ago by MT Newswires
  11 hours ago by MT Newswires
  Companies Mentioned: GSK, CVAC
- GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review, from 13 hours ago by MT Newswires
  13 hours ago by MT Newswires
  Companies Mentioned: GSK
Yesterday
- Sector Update: Health Care Stocks Rise Late Afternoon, from 3:56PM ET on Tuesday Apr 23, 2024 by MT Newswires
  3:56PM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: SNY, UNH, ABEO, DHR
- Sector Update: Health Care, from 3:37PM ET on Tuesday Apr 23, 2024 by MT Newswires
  3:37PM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: SNY
- Market Chatter: Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business, from 1:59PM ET on Tuesday Apr 23, 2024 by MT Newswires
  1:59PM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: SNY
- --Argus Cuts Price Target on Gilead Sciences to $75 From $85, from 7:54AM ET on Tuesday Apr 23, 2024 by MT Newswires
  7:54AM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: GILD
Apr 22, 2024
- Sector Update: Health Care Stocks Rise in Monday Afternoon Trading, from 1:55PM ET on Monday Apr 22, 2024 by MT Newswires
  1:55PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: SNY, GH, CAH
- Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team, from 12:01PM ET on Monday Apr 22, 2024 by MT Newswires
  12:01PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: HMC, KR, TSLA, SNY, VZ, WFC, CMG, AMZN, TFC, CNHI
- Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer, from 11:40AM ET on Monday Apr 22, 2024 by MT Newswires
  11:40AM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: SNY

Amgen Inc
NASDAQ:AMGNUnited States

Search Criteria

Apr 18, 2024

DJ Amgen Is Maintained at Neutral by UBS, from 7:41AM ET on Thursday Apr 18, 2024 by Dow Jones

Apr 17, 2024

--UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating, from 9:57AM ET on Wednesday Apr 17, 2024 by MT Newswires

DJ Amgen Is Maintained at Buy by TD Cowen, from 6:12AM ET on Wednesday Apr 17, 2024 by Dow Jones

Apr 16, 2024

Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease, from 5:56PM ET on Tuesday Apr 16, 2024 by MT Newswires

AMGEN TO PRESENT TEZSPIRE(R) PHASE 2A COPD DATA AT ATS 2024, from 5:26PM ET on Tuesday Apr 16, 2024 by Dow Jones

Peers Headlines

Today

--HSBC Upgrades Gilead Sciences to Hold From Reduce, Price Target is $69, from 10 hours ago by MT Newswires

CureVac Begins Early Stage Portion of Investigational Vaccine Trial, from 11 hours ago by MT Newswires

GSK's Application for Jemperli's Expanded Indication Accepted by FDA for Priority Review, from 13 hours ago by MT Newswires

Yesterday

Sector Update: Health Care Stocks Rise Late Afternoon, from 3:56PM ET on Tuesday Apr 23, 2024 by MT Newswires

Sector Update: Health Care, from 3:37PM ET on Tuesday Apr 23, 2024 by MT Newswires

Market Chatter: Sanofi Asks Banks to Pitch for Roles on Separation of Consumer Health Care Business, from 1:59PM ET on Tuesday Apr 23, 2024 by MT Newswires

--Argus Cuts Price Target on Gilead Sciences to $75 From $85, from 7:54AM ET on Tuesday Apr 23, 2024 by MT Newswires

Apr 22, 2024

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading, from 1:55PM ET on Monday Apr 22, 2024 by MT Newswires

Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team, from 12:01PM ET on Monday Apr 22, 2024 by MT Newswires

Market Chatter: Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer, from 11:40AM ET on Monday Apr 22, 2024 by MT Newswires